Related Experiment Video
Updated: Apr 15, 2026

Lighting Up the Pathways to Caspase Activation Using Bimolecular Fluorescence Complementation
Published on: March 5, 2018
The tumor-modulatory effects of Caspase-2 and Pidd1 do not require the scaffold protein Raidd
L Peintner1, L Dorstyn2, S Kumar2
1Division of Developmental Immunology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Abstract:
The receptor-interacting protein-associated ICH-1/CED-3 homologous protein with a death domain (RAIDD/CRADD) functions as a dual adaptor and is a constituent of different multi-protein complexes implicated in the regulation of inflammation and cell death. Within the PIDDosome complex, RAIDD connects the cell death-related protease, Caspase-2, with the p53-induced protein with a death domain 1 (PIDD1). As such, RAIDD has been implicated in DNA-damage-induced apoptosis as well as in tumorigenesis. As loss of Caspase-2 leads to an acceleration of tumor onset in the Emicro-Myc mouse lymphoma model, whereas loss of Pidd1 actually delays onset of this disease, we set out to interrogate the role of Raidd in cancer in more detail. Our data obtained analyzing Emicro-Myc/Raidd(-/-) mice indicate that Raidd is unable to protect from c-Myc-driven lymphomagenesis. Similarly, we failed to observe a modulatory effect of Raidd deficiency on DNA-damage-driven cancer. The role of Caspase-2 as a tumor suppressor and that of Pidd1 as a tumor promoter can therefore be uncoupled from their ability to interact with the Raidd scaffold, pointing toward the existence of alternative signaling modules engaging these two proteins in this context.
Insights
Receptor-interacting protein-associated ICH-1/CED-3 homologous protein with a death domain (RAIDD) does not influence c-Myc-driven lymphomagenesis or DNA-damage-induced cancer. RAIDD
Area of Science:
- Molecular biology
- Cell death regulation
- Cancer research
Background:
- Receptor-interacting protein-associated ICH-1/CED-3 homologous protein with a death domain (RAIDD) is a dual adaptor protein involved in inflammation and cell death.
- RAIDD is a component of the PIDDosome complex, linking Caspase-2 and PIDD1, and has been implicated in apoptosis and tumorigenesis.
- Caspase-2 acts as a tumor suppressor, while PIDD1 acts as a tumor promoter in the Emicro-Myc mouse lymphoma model.
Purpose of the Study:
- To investigate the role of RAIDD in cancer, particularly in relation to Caspase-2 and PIDD1 functions.
- To determine if RAIDD deficiency modulates lymphomagenesis or DNA-damage-induced cancer in mice.
Main Methods:
- Analysis of Emicro-Myc/Raidd(-/-) mice to assess lymphomagenesis.
- Evaluation of Raidd deficiency's effect on DNA-damage-driven cancer models.
Main Results:
- Raidd deficiency did not protect against c-Myc-driven lymphomagenesis in Emicro-Myc/Raidd(-/-) mice.
- Loss of Raidd did not significantly affect the onset or progression of DNA-damage-induced cancer.
- The tumor suppressor role of Caspase-2 and the tumor promoter role of PIDD1 are independent of their interaction with the RAIDD scaffold.
Conclusions:
- RAIDD does not play a significant role in modulating Caspase-2 or PIDD1 functions in the context of c-Myc-driven lymphomagenesis or DNA-damage-induced cancer.
- Alternative signaling pathways likely mediate the tumor suppressor function of Caspase-2 and the tumor promoter function of PIDD1.
Related Concept Videos
Caspases
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway
Inhibition of Cdk Activity

